Data are from the Swedish Medical Birth Register, National Patient Register and Swedish Renal Register. Data cannot be put into a public data repository due to Swedish confidentiality regulations for registry data. Details on the application procedures for data usage is available on the home pages of the respective registries: the Medical Birth Register (<https://www.socialstyrelsen.se/en/statistics-and-data/registers/alla-register/the-swedish-medical-birth-register/>); the National Patient Register (<https://www.socialstyrelsen.se/en/statistics-and-data/registers/alla-register/the-national-patient-register/>); and the Swedish Renal Register (<https://www.medscinet.net/snr/>). Information on how to access the data can also be found using these contact details: Phone +46(0)75-247 30 00, email <socialstyrelsen@socialstyrelsen.se>.

Introduction {#sec007}
============

Preeclampsia is characterised by the development of de novo hypertension after 20 weeks' gestation, in the presence of either proteinuria, maternal organ dysfunction (including renal insufficiency), or evidence of foetal growth restriction \[[@pmed.1003255.ref001]\]. It complicates 3%--5% of pregnancies worldwide \[[@pmed.1003255.ref002]\], and affected women are at higher risk of long-term cardiovascular disease (CVD) \[[@pmed.1003255.ref003]--[@pmed.1003255.ref005]\]. Preeclampsia has also been described as a reversible kidney disease that typically self-resolves within 3 months of delivery \[[@pmed.1003255.ref006]\]. However, there is increasing evidence that some women experience sustained renal dysfunction, and large cohort studies have reported an increased risk of end-stage kidney disease (ESKD) \[[@pmed.1003255.ref007]--[@pmed.1003255.ref010]\]. Biological mechanisms are uncertain; this may be due to lasting vascular endothelial dysfunction related to elevated levels of anti-angiogenic proteins---such as soluble fms-like tyrosine kinase-1---or it may be due to direct glomerular damage related to underexpression of nuclear factor erythroid 2--related factor 2 (NRF-2) \[[@pmed.1003255.ref011]--[@pmed.1003255.ref013]\]. Other changes in the renin-angiotensin-aldosterone system, metabolic system, and factors causing endothelial dysfunction may also be involved.

Chronic kidney disease (CKD) is much more prevalent than ESKD, and although it may be considered a precursor to ESKD, the evidence for associations between preeclampsia and CKD has been inconsistent to date \[[@pmed.1003255.ref006], [@pmed.1003255.ref014]\]. Cohort studies from Scotland and Denmark have reported increased risk of CKD following preeclampsia \[[@pmed.1003255.ref015], [@pmed.1003255.ref016]\], but these findings have not been replicated elsewhere \[[@pmed.1003255.ref017], [@pmed.1003255.ref018]\]. The underlying causes of CKD are wide-ranging, and it is plausible that hypertensive disorders of pregnancy (HDP) differentially affect the risk of CKD subtypes, but few studies have considered this when investigating associations. Moreover, while the risk of ESKD is higher among women who experience preeclampsia concurrently with preterm delivery or small for gestational age (SGA) \[[@pmed.1003255.ref007], [@pmed.1003255.ref008]\], it is unclear whether this is also the case for CKD.

Gestational hypertension is another common hypertensive disorder that arises de novo after 20 weeks' gestation in the absence of proteinuria and is not typically accompanied by organ dysfunction or foetal growth restriction \[[@pmed.1003255.ref001]\]. Although gestational hypertension is regarded as an independent risk factor for subsequent CVD \[[@pmed.1003255.ref019]\], few studies have investigated associations with CKD \[[@pmed.1003255.ref014]\]. The aim of this study is to investigate whether HDP (preeclampsia, gestational hypertension) are associated with the long-term risk of maternal CKD, and to identify whether the risk differs according to CKD aetiology or by concurrent preterm delivery or SGA.

Methods {#sec008}
=======

Study population {#sec009}
----------------

Women who had singleton live births between January 1, 1973, and December 31, 2012, were identified from the Swedish Medical Birth Register (MBR; established 1973). The MBR contains detailed information on over 96% of births in Sweden \[[@pmed.1003255.ref020]\]. We used hospitalisation data from the Swedish National Patient Register (NPR; established 1964) and the Swedish Renal Register (SRR; established 1991) to identify women who developed CKD during follow-up, until December 31, 2013 (study end date). Data from all registers were linked using the anonymised unique national identification number, which is issued to all citizens of Sweden. Data from the Swedish Death Register and Migration Register were also available until December 31, 2013, and were used for censoring. We excluded multiple pregnancies (*n* = 148,339) and pregnancies with implausible dates of delivery (*n* = 312) from all analyses at baseline. We also excluded women who had stillbirths (*n* = 14,107) to avoid potential confounding since they are more likely to experience preeclampsia compared with women who only have live births, and they are at increased risk of long-term CKD \[[@pmed.1003255.ref021]\] ([S1 Fig](#pmed.1003255.s001){ref-type="supplementary-material"}).

We identified women with pre-pregnancy CKD, ESKD, CVD, chronic hypertension, diabetes (type 1 or 2), systemic lupus erythematosus (SLE), systemic sclerosis, coagulopathies, hemoglobinopathies, or vasculitides from the MBR, and they were excluded at baseline. We also excluded all women in the NPR who were admitted to hospital with any of those diagnoses before their first date of delivery. We used 3 iterations of International Classification of Diseases (ICD) coding to identify pre-existing diseases in the NPR: ICD-8 coding from 1973 to 1986, ICD-9 coding from 1987 to 1996, and ICD-10 coding from 1997 to 2013. The full list of ICD codes used in the study is summarised in [S1 Table](#pmed.1003255.s002){ref-type="supplementary-material"}. Furthermore, we identified hospital admissions and outpatient reviews for preeclampsia and gestational diabetes in the NPR and used this information to supplement data in the MBR.

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S2 Table](#pmed.1003255.s004){ref-type="supplementary-material"}). All data were anonymised and nonidentifiable. Ethical approval was granted by the Swedish Ethical Review Authority in Stockholm (Regionala Etikprovningsnamnden Stockholm) (Dnr 2012/397-31/1) and by the Social Research and Ethics Committee, University College Cork (2019--109).

Exposure variables {#sec010}
------------------

Preeclampsia was the main exposure of interest and was identified in the MBR and NPR using ICD codes. Preeclampsia was defined as a diastolic blood pressure of \>90 mmHg with proteinuria (≥0.3 g/day or ≥1+ on a urine dipstick) \[[@pmed.1003255.ref008]\]. We included cases of eclampsia and Haemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome with preeclampsia because these conditions are rare in Sweden and there were too few affected women to allow for separate groups. However, we excluded women who developed preeclampsia superimposed on chronic hypertension, since women with pre-pregnancy hypertension were excluded at baseline.

Diagnoses of preeclampsia in the MBR have been validated previously and have high positive predictive value (PPV) for ICD-9 coded diagnoses when compared with medical records but lower PPV for ICD-8 coded diagnoses \[[@pmed.1003255.ref022]\]. In the current study, all analyses included women who had singleton live births with or without preeclampsia from 1973 onwards. Analyses were repeated after restricting the study population to those with a first live birth from 1987 onwards (thus restricted to ICD-9 and ICD-10 coded diagnoses alone). Since 2014, proteinuria is no longer a requirement for a preeclampsia diagnosis in Sweden \[[@pmed.1003255.ref001]\]. However, because our study ended on December 31, 2013, this did not affect our analysis.

Preeclampsia was included in statistical models as a time-dependent variable. Women were considered unexposed (i) if they never developed preeclampsia, or (ii) from the date of their index delivery (without preeclampsia) until the date of delivery of their first preeclamptic pregnancy. Women were considered 'exposed' from the date of their first preeclamptic delivery onwards, irrespective of subsequent pregnancy outcomes. For example, if a woman had 3 live births and only experienced preeclampsia in her second pregnancy, she was considered unexposed between delivery 1 and delivery 2 but was considered exposed from delivery 2 onwards (despite the non-preeclamptic third pregnancy).

In accordance with international guidelines, we did not classify preeclampsia as mild or severe disease \[[@pmed.1003255.ref001]\]. However, preeclampsia was considered together with SGA and preterm delivery respectively, and these may be considered proxy markers of severity \[[@pmed.1003255.ref023]\]. For SGA, a series of dummy variables were included to represent nonoverlapping scenarios: (i) preeclampsia alone, (ii) SGA alone, or (iii) preeclampsia and SGA (co-occurring). SGA was defined in the MBR as a birth weight of 2 SDs below the sex-specific and gestational age distributions, according to Swedish weight-based growth standards \[[@pmed.1003255.ref024]\], and was treated as a time-dependent variable.

Preterm delivery was defined as any delivery before 37 weeks' gestation. This was largely estimated based on second trimester ultrasound (from 1982 onwards) but was estimated from maternal report of last menstrual period (LMP) prior to that \[[@pmed.1003255.ref020]\]. Preterm deliveries were categorised as moderate (32 weeks to 36+6 weeks), very (28 weeks to 31+6 weeks), or extremely preterm (\<28 weeks gestation). The latter two categories (very/extremely preterm) were combined in analyses due to small numbers. Maternal exposure to preterm delivery was time dependent and was allowed to change multiple times across different pregnancies, but exposure status was always based on the earliest gestation of any previous delivery.

Furthermore, we considered the effect of recurrent preeclampsia on CKD risk among women who had exactly 2 deliveries. We categorised these women as follows: (1) no preeclampsia, (2) preeclampsia in one pregnancy, and (3) preeclampsia in both pregnancies.

Gestational hypertension was a secondary exposure variable of interest and was defined as blood pressure of at least 140/90 mm Hg (in at least 2 readings 6 or more hours apart), without proteinuria, occurring after 20 weeks' gestation up to the date of delivery. It was included in statistical models as a time-dependent variable.

Outcome variables {#sec011}
-----------------

### CKD {#sec012}

Maternal CKD was the primary outcome. This was defined by a recorded diagnosis of CKD in the SRR or based on a primary or secondary diagnosis of CKD in the NPR (using ICD codes). The earliest date at which a woman appeared in either the SRR or NPR was taken as her date of diagnosis, and she was censored at that date irrespective of subsequent deliveries. Women who had an identifiable congenital or genetic cause of CKD were excluded at baseline. We only considered women who were diagnosed with CKD at least 3 months after the last pregnancy, to avoid any potential misclassification with acute kidney injury or any transient renal dysfunction related to preeclampsia.

We categorised CKD diagnosis in broad aetiologies; categories were selected a priori based on guidance from the National Kidney Foundation \[[@pmed.1003255.ref025]\], prior research \[[@pmed.1003255.ref008], [@pmed.1003255.ref016]\], and clinical advice from consultant nephrologists. The following categories were used: tubulointerstitial CKD, glomerular/proteinuric CKD, hypertensive CKD, diabetic CKD, and other/unspecified CKD. The ICD codes used to define CKD in each category are shown in [S1 Table](#pmed.1003255.s002){ref-type="supplementary-material"}. CKD subtype/aetiology was always based on the initial CKD diagnosis, when each woman first appeared in either the SRR or NPR.

### Covariates {#sec013}

The following covariates were selected a priori and adjusted for: maternal age, country of origin, education level, antenatal BMI at first pregnancy, smoking during pregnancy, gestational diabetes, parity, and gestational hypertension. Information on the mother's highest level of educational achievement was available from the Swedish Education Register. Maternal smoking was based on any reported smoking during pregnancy, either at first antenatal visit or at 30--32 weeks' gestation. Maternal BMI was measured at first antenatal visit. Smoking status and BMI only became available from 1982 onwards and were more complete after 1987. Missing indicator variables were created to control for missing data on smoking and BMI.

Maternal exposure to gestational diabetes and gestational hypertension were time-dependent covariates, where women were considered exposed from their date of first delivery with gestational diabetes or gestational hypertension respectively. In the analysis of gestational hypertension and maternal CKD, we adjusted for preeclampsia as a time-dependent covariate.

Statistical analysis {#sec014}
--------------------

Each woman's entry date in the study was the date of her first live birth. The association between preeclampsia and risk of maternal CKD was estimated using the Kaplan-Meier method. We used multivariable Cox proportional hazard regression models to estimate age-adjusted and fully adjusted hazard ratios (aHRs) and 95% CIs for the associations between preeclampsia and maternal CKD. We followed women from date of entry until date of CKD diagnosis or study end date (December 31, 2013), whichever came first. Thus, women stopped contributing person-time once they were diagnosed with CKD, and any subsequent pregnancies were not included in the analysis. Women who died or emigrated during follow-up were censored on that date. Thus, the reported HRs are the HRs that would be seen if mortality could be eliminated during the study period \[[@pmed.1003255.ref026]\]. We used log cumulative hazard plots to ensure that the proportional hazards assumption was met.

Our analysis of preeclampsia and CKD was pre-planned using 4 separate models. Model 1 explored the association between any preeclampsia and CKD (versus women who never had preeclampsia). Model 2 explored the association between preeclampsia ± SGA and CKD. Model 3 explored the association between preeclampsia ± preterm delivery and CKD. Model 4 explored the association between recurrent preeclampsia and CKD among women who had 2 live births during the study period. In each model, we considered all diagnoses of CKD collectively (overall CKD) and considered the 5 subtypes of CKD separately. Models were first adjusted for age, and then adjusted fully for all relevant covariates. In the analysis of each CKD subtype, follow-up stopped when the woman received her first diagnosis of CKD.

We conducted 3 pre-planned sensitivity analyses. Firstly, we restricted the dataset to women whose first birth occurred from 1987 onwards, when NPR coverage was more complete. The PPV for preeclampsia and gestational hypertension diagnoses was higher from this time, and information on maternal BMI and smoking was more comprehensive \[[@pmed.1003255.ref020], [@pmed.1003255.ref022]\]. Secondly, we categorised all births with information on maternal BMI (from 1982 onwards) according to whether mothers were obese or nonobese at the time of delivery. Thirdly, we explored the effect of excluding women who developed postpartum hypertension, to establish whether associations between preeclampsia and CKD persisted among women who remained normotensive after their last pregnancy. We undertook this analysis for all subtypes except for hypertensive CKD.

Finally, we investigated associations between gestational hypertension and CKD (versus women who never had gestational hypertension). Again, we considered all diagnoses of CKD collectively (overall CKD) and separate CKD subtypes. All analyses were performed using Stata version 15 (StataCorp, College Station, Texas).

Results {#sec015}
=======

The study cohort consisted of 1,924,409 unique women who had 3,726,554 singleton live births, followed up for a total of 42,118,889 person-years. The mean age at first delivery was 27.0 (± SD 5.1) years, and median follow-up time was 20.7 years (interquartile range \[IQR\] 9.9--30.0 years). There were 53,265 deaths (2.8%).

There were 90,917 women (4.7%) diagnosed with preeclampsia at least once ([Table 1](#pmed.1003255.t001){ref-type="table"}). They were more likely to be native Swedes, overweight or obese, more likely to have experienced other adverse pregnancy outcomes (preterm delivery, SGA, or gestational diabetes), and less likely to be smokers compared to women who never experienced preeclampsia.

10.1371/journal.pmed.1003255.t001

###### Maternal characteristics and pregnancy outcomes among women who had live births between 1973 and 2012 in Sweden, stratified by exposure to preeclampsia (*N* = 1,924,409).

![](pmed.1003255.t001){#pmed.1003255.t001g}

  ------------------------------------------------------------------------------------------------------------------
                                                 No preeclampsia, *n* (%)\   Preeclampsia, *n* (%)\   *p*-Value
                                                 *n* = 1,833,492 (95.3%)     *n* = 90,917 (4.7%)      
  ---------------------------------------------- --------------------------- ------------------------ --------------
  **Age at first pregnancy (years)**                                                                  *p* \< 0.001

  \<20                                           103,561 (5.7)               5,971 (6.6)              

  20--29                                         1,184,635 (64.6)            59,030 (64.9)            

  30--39                                         520,110 (28.4)              24,424 (26.9)            

  ≥40                                            25,186 (1.4)                1,492 (1.6)              

  **Native country**                                                                                  *p* \< 0.001

  Sweden                                         1,550,745 (84.6)            80,663 (88.7)            

  Elsewhere                                      282,747 (15.4)              10,254 (11.3)            

  **Education level**                                                                                 *p* \< 0.001

  Less than upper secondary                      243,022 (13.3)              11,571 (12.7)            

  Upper secondary                                825,165 (45.0)              44,073 (48.5)            

  Third level                                    726,169 (39.6)              34,078 (37.5)            

  Missing                                        39,136 (2.1)                1,195 (1.3)              

  **BMI in early pregnancy (kg/m**^**2**^**)**                                                        *p* \< 0.001

  Underweight: \<18.5                            44,069 (2.4)                1,391 (1.5)              

  Normal: 18.5--24.9                             676,382 (36.9)              28,187 (31.0)            

  Overweight: 25--29.9                           179,529 (9.8)               12,669 (13.9)            

  Obesity: ≥30                                   62,487 (3.4)                7,225 (8.0)              

  Missing                                        871,025 (47.5)              41,445 (45.6)            

  **Maternal smoking**                                                                                *p* \< 0.001

  No                                             971,826 (53.0)              52,761 (58.0)            

  Yes                                            198,463 (10.8)              7,704 (8.5)              

  Missing                                        663,203 (36.2)              30,452 (33.5)            

  **Gestational diabetes (ever)**                                                                     *p* \< 0.001

  No                                             1,817,243 (99.1)            88,935 (97.8)            

  Yes                                            16,249 (0.9)                1,982 (2.2)              

  **Preterm delivery (ever)**                                                                         *p* \< 0.001

  No                                             1,695,439 (92.5)            70,383 (77.4)            

  Yes                                            138,188 (7.5)               20,581 (22.6)            

  **SGA (ever)**                                                                                      *p* \< 0.001

  No                                             1,747,083 (95.4)            77,094 (84.9)            

  Yes                                            84,540 (4.6)                13,751 (15.1)            

  **Decade of first birth**                                                                           *p* \< 0.001

  1973--1979                                     490,813 (26.8)              21,231 (23.4)            

  1980--1989                                     400,822 (21.9)              21,524 (23.7)            

  1990--1999                                     399,164 (21.8)              21,950 (24.1)            

  2000--2012                                     542,693 (29.6)              26,212 (28.8)            
  ------------------------------------------------------------------------------------------------------------------

**Abbreviation:** SGA, small for gestational age

From 1973 to 2013, 18,477 women (0.9%) developed CKD, of whom 2,813 (15.2%) had tubulointerstitial CKD, 6,068 (32.8%) had glomerular/proteinuric CKD, 797 (4.3%) had hypertensive CKD, 1,226 (6.6%) had diabetic CKD, and 7,573 (41.0%) had CKD due to other/unspecified causes. The median time to CKD diagnosis after first live birth (overall) was 16.8 years (IQR 7.2--26.5). The median time to CKD diagnosis varied by aetiology: tubulointerstitial CKD: 14.6 years (IQR 5.8--24.2); glomerular/proteinuric CKD: 10.9 years (IQR 4.4--18.5); hypertensive CKD: 22.2 years (IQR 15.0--30.1); diabetic CKD: 22.1 years (IQR 12.5--29.4); and other/unspecified CKD: 22.1 years (IQR 11.5--30.0). For all CKD aetiologies, the median time to diagnosis was significantly shorter in women who had previous preeclampsia and was shortest for glomerular/proteinuric CKD (median 7.7 years; IQR 2.0--15.7) ([S3 Table](#pmed.1003255.s005){ref-type="supplementary-material"}).

Preeclampsia {#sec016}
------------

Women who had ever experienced preeclampsia were at higher risk of developing CKD compared with women who never had preeclampsia (aHR 1.92, 95% CI 1.83--2.03, *p* \< 0.001). This risk differed by CKD subtype and was highest for hypertensive CKD (aHR 3.72, 95% CI 3.05--4.53, *p* \< 0.001), diabetic CKD (aHR 3.94, 95% CI 3.38--4.60, *p* \< 0.001), and glomerular/proteinuric CKD (aHR 2.06, 95% CI 1.88--2.26, *p* \< 0.001). The risk was lower for other/unspecified CKD (aHR 1.51, 95% CI 1.38--1.65, *p* \< 0.001) and tubulointerstitial CKD (aHR 1.44, 95% CI 1.24--1.68, *p* \< 0.001).

There was little difference in CKD risk between preeclamptic women who experienced concurrent SGA and those who did not ([Table 2](#pmed.1003255.t002){ref-type="table"}). Hypertensive CKD risk was the exception and was more likely in women who had preeclampsia + SGA (versus neither, aHR 5.23, 95% CI 3.51--7.79, *p* \< 0.001). Women who had SGA alone (without preeclampsia) were also at higher risk of CKD, but the associations were less marked than for preeclampsia. Women who had preeclampsia and who delivered at earlier gestation also had higher risk of CKD ([Table 3](#pmed.1003255.t003){ref-type="table"}). Women with at least one preeclamptic delivery before 32 weeks' gestation were at particularly high risk of CKD (versus normal term deliveries, aHR 3.19, 95% CI 2.53--4.02, *p* \< 0.001).

10.1371/journal.pmed.1003255.t002

###### HRs for maternal CKD by history of preeclampsia and SGA, among women who had live births between 1973 and 2012 in Sweden (*N* = 1,924,409).

![](pmed.1003255.t002){#pmed.1003255.t002g}

                            CKD, *n*                         Age-adjusted        Fully adjusted       
  ------------------------- -------------------------------- ------------------- -------------------- -------------------
  **Overall CKD**                                                                                     
  No preeclampsia, no SGA   15,783                           1.0                 1.0                  
  Preeclampsia only         1,318                            2.08 (1.96--2.20)   1.96 (1.85--2.08)    
  SGA only                  1,150                            1.45 (1.36--1.53)   1.32 (1.24--1.40)    
  Preeclampsia and SGA      226                              2.11 (1.85--2.41)   1.95 (1.71--2.22)    
  **1.**                    **Tubulointerstitial CKD**                                                
                            No preeclampsia, no SGA          2,458               1.0                  1.0
                            Preeclampsia only                157                 1.52 (1.29--1.78)    1.47 (1.25--1.73)
                            SGA only                         171                 1.45 (1.24--1.70)    1.30 (1.11--1.51)
                            Preeclampsia and SGA             27                  1.51 (1.03--2.20)    1.41 (0.97--2.07)
  **2.**                    **Glomerular/proteinuric CKD**                                            
                            No preeclampsia, no SGA          5,151               1.0                  1.0
                            Preeclampsia only                425                 2.10 (1.90--2.32)    2.11 (1.90--2.33)
                            SGA only                         417                 1.61 (1.45--1.77)    1.46 (1.32--1.62)
                            Preeclampsia and SGA             75                  2.22 (1.76--2.78)    2.16 (1.71--2.71)
  **3.**                    **Hypertensive CKD**                                                      
                            No preeclampsia, no SGA          610                 1.0                  1.0
                            Preeclampsia only                104                 4.43 (3.59--5.46)    3.60 (2.90--4.47)
                            SGA only                         57                  1.76 (1.34--2.30)    1.54 (1.17--2.02)
                            Preeclampsia and SGA             26                  6.82 (4.60--10.11)   5.23 (3.51--7.79)
  **4.**                    **Diabetic CKD**                                                          
                            No preeclampsia, no SGA          954                 1.0                  1.0
                            Preeclampsia only                189                 5.14 (4.40--6.01)    4.03 (3.42--4.74)
                            SGA only                         57                  1.16 (0.89--1.51)    1.05 (0.80--1.37)
                            Preeclampsia and SGA             26                  4.28 (2.90--6.33)    3.49 (2.36--5.16)
  **5.**                    **Other/unspecified CKD**                                                 
                            No preeclampsia, no SGA          6,611               1.0                  1.0
                            Preeclampsia only                443                 1.65 (1.50--1.81)    1.54 (1.40--1.70)
                            SGA only                         448                 1.34 (1.22--1.47)    1.24 (1.13--1.37)
                            Preeclampsia and SGA             72                  1.59 (1.26--2.00)    1.46 (1.15--1.84)

\*All *p* \< 0.001.

HRs represent separate Cox regression models for associations between preeclampsia and maternal CKD. Preeclampsia was a time-dependent variable. Fully adjusted models controlled for maternal age, country of origin, education level, parity, maternal BMI, smoking in pregnancy, exposure to gestational diabetes, and exposure to gestational hypertension. Models were stratified by year of delivery.

**Abbreviations:** CKD, chronic kidney disease; HR, hazard ratio; SGA, small for gestational age

10.1371/journal.pmed.1003255.t003

###### HRs for maternal CKD by history of preeclampsia and preterm delivery, among women who had live births between 1973 and 2012 in Sweden (*N* = 1,924,409).

![](pmed.1003255.t003){#pmed.1003255.t003g}

                                                     CKD, *n*                                           Age-adjusted                              Fully adjusted        
  -------------------------------------------------- -------------------------------------------------- ----------------------------------------- --------------------- --------------------
  **Overall CKD**                                                                                                                                                       
  Term delivery, no preeclampsia                     15,134                                             1.0                                       1.0                   
  Moderate preterm delivery, no preeclampsia         1,552                                              1.58 (1.50--1.66)                         1.46 (1.39--1.54)     
  Very/extremely preterm delivery, no preeclampsia   247                                                1.86 (1.64--2.11)                         1.63 (1.44--1.85)     
  Term delivery + preeclampsia                       1,196                                              1.98 (1.87--2.10)                         1.87 (1.76--1.99)     
  Moderate preterm delivery + preeclampsia           276                                                2.65 (2.34--3.00)                         2.52 (2.23--2.85)     
  Very/extremely preterm delivery + preeclampsia     72                                                 3.34 (2.65--4.21)                         3.19 (2.53--4.02)     
  **1.**                                             **Tubulointerstitial CKD**                                                                                         
                                                     Term delivery, no preeclampsia                     2,365                                     1.0                   1.0
                                                     Moderate preterm delivery, no preeclampsia         220                                       1.38 (1.20--1.58)     1.26 (1.09--1.44)
                                                     Very/extremely preterm delivery, no preeclampsia   44                                        2.05 (1.52--2.76)     1.75 (1.30--2.36)
                                                     Term delivery + preeclampsia                       146                                       1.50 (1.26--1.77)     1.45 (1.22--1.72)
                                                     Moderate preterm delivery + preeclampsia           24                                        1.39 (0.93--2.08)     1.37 (0.91--2.05)
                                                     Very/extremely preterm delivery + preeclampsia     14                                        3.30 (1.95--5.58)     3.27 (1.93--5.54)
  **2.**                                             **Glomerular/proteinuric CKD**                                                                                     
                                                     Term delivery, no preeclampsia                     4,982                                     1.0                   1.0
                                                     Moderate preterm delivery, no preeclampsia         508                                       1.59 (1.45--1.74)     1.48 (1.35--1.62)
                                                     Very/extremely preterm delivery, no preeclampsia   78                                        1.83 (1.46--2.29)     1.59 (1.27--1.98)
                                                     Term delivery + preeclampsia                       393                                       1.98 (1.78--2.20)     1.98 (1.78--2.20)
                                                     Moderate preterm delivery + preeclampsia           81                                        2.64 (2.12--3.29)     2.69 (2.16--3.35)
                                                     Very/extremely preterm delivery + preeclampsia     26                                        3.87 (2.63--5.70)     3.88 (2.64--5.71)
  **3.**                                             **Hypertensive CKD**                                                                                               
                                                     Term delivery, no preeclampsia                     573                                       1.0                   1.0
                                                     Moderate preterm delivery, no preeclampsia         77                                        2.14 (1.68--2.71)     1.92 (1.51--2.45)
                                                     Very/extremely preterm delivery, no preeclampsia   17                                        3.50 (2.16--5.67)     2.98 (1.84--4.84)
                                                     Term delivery + preeclampsia                       104                                       4.49 (3.63--5.57)     3.65 (2.92--4.55)
                                                     Moderate preterm delivery + preeclampsia           22                                        7.06 (4.60--10.83)    5.47 (3.55--8.43)
                                                     Very/extremely preterm delivery + preeclampsia     [\*\*](#t003fn002){ref-type="table-fn"}   6.94 (2.59--18.60)    5.74 (2.14--15.40)
  **4.**                                             **Diabetic CKD**                                                                                                   
                                                     Term delivery, no preeclampsia                     839                                       1.0                   1.0
                                                     Moderate preterm delivery, no preeclampsia         150                                       2.85 (2.40--3.40)     2.54 (2.13--3.03)
                                                     Very/extremely preterm delivery, no preeclampsia   22                                        3.12 (2.04--4.76)     2.55 (1.66--3.89)
                                                     Term delivery + preeclampsia                       155                                       4.62 (3.87--5.51)     3.69 (3.08--4.41)
                                                     Moderate preterm delivery + preeclampsia           56                                        11.70 (8.91--15.36)   8.80 (6.67--11.60)
                                                     Very/extremely preterm delivery + preeclampsia     [\*\*](#t003fn002){ref-type="table-fn"}   4.10 (1.53--10.96)    3.18 (1.19--8.51)
  **5.**                                             **Other/unspecified CKD**                                                                                          
                                                     Term delivery, no preeclampsia                     6,375                                     1.0                   1.0
                                                     Moderate preterm delivery, no preeclampsia         597                                       1.43 (1.32--1.56)     1.34 (1.24--1.46)
                                                     Very/extremely preterm delivery, no preeclampsia   86                                        1.52 (1.23--1.88)     1.37 (1.10--1.69)
                                                     Term delivery + preeclampsia                       398                                       1.61 (1.45--1.78)     1.50 (1.36--1.67)
                                                     Moderate preterm delivery + preeclampsia           93                                        1.78 (1.42--2.25)     1.68 (1.33--2.12)
                                                     Very/extremely preterm delivery + preeclampsia     24                                        2.64 (1.78--3.94)     2.50 (1.68--3.74)

\*All *p* \< 0.001.

\*\*Exact number not reported as cell count ≤5.

HRs represent separate Cox regression models for associations between preeclampsia and maternal CKD. Preeclampsia was a time-dependent variable. Fully adjusted models controlled for maternal age, country of origin, education level, parity, maternal BMI, smoking in pregnancy, exposure to gestational diabetes, and exposure to gestational hypertension. Models were stratified by year of delivery.

**Abbreviations:** CKD, chronic kidney disease; HR, hazard ratio; ne, not estimable; SGA, small for gestational age

A total of 855,095 women in the sample had only 2 births, of whom 4.4% (*n* = 37,322) had preeclampsia once and 0.5% (*n* = 4,335) had preeclampsia twice (recurrent preeclampsia). Compared with women who never had preeclampsia, those who had recurrent preeclampsia had the greatest risk of developing any form of CKD (aHR 2.64, 95% CI 2.14--3.25, *p* \< 0.001) ([Table 4](#pmed.1003255.t004){ref-type="table"}). Again, the risk was stronger for hypertensive CKD (aHR 5.30, 95% CI 2.47--11.36, *p* \< 0.001), diabetic CKD (aHR 6.80, 95% CI 3.96--11.68, *p* \< 0.001), and glomerular/proteinuric CKD (aHR 3.42, 95% CI 2.44--4.78, *p* \< 0.001).

10.1371/journal.pmed.1003255.t004

###### HRs for maternal CKD by history of recurrent preeclampsia, among women who had live births between 1973 and 2012 in Sweden (*N* = 855,095).

![](pmed.1003255.t004){#pmed.1003255.t004g}

                                                  CKD, *n*                                        Age-adjusted        Fully adjusted       
  ----------------------------------------------- ----------------------------------------------- ------------------- -------------------- --------------------
  **Overall CKD**                                                                                                                          
  Two pregnancies without preeclampsia            6,326                                           1.0                 1.0                  
  Two pregnancies, one episode of preeclampsia    551                                             1.90 (1.74--2.07)   1.82 (1.66--1.99)    
  Two pregnancies, two episodes of preeclampsia   90                                              2.77 (2.25--3.41)   2.64 (2.14--3.25)    
  **1.**                                          **Tubulointerstitial CKD**                                                               
                                                  Two pregnancies without preeclampsia            1,054               1.0                  1.0
                                                  Two pregnancies, one episode of preeclampsia    78                  1.59 (1.26--2.00)    1.58 (1.25--1.99)
                                                  Two pregnancies, two episodes of preeclampsia   10                  1.77 (0.95--3.30)    1.74 (0.93--3.25)
  **2.**                                          **Glomerular/proteinuric CKD**                                                           
                                                  Two pregnancies without preeclampsia            2,062               1.0                  1.0
                                                  Two pregnancies, one episode of preeclampsia    183                 1.94 (1.67--2.26)    2.02 (1.73--2.35)
                                                  Two pregnancies, two episodes of preeclampsia   35                  3.32 (2.38--4.64)    3.42 (2.44--4.78)
  **3.**                                          **Hypertensive CKD**                                                                     
                                                  Two pregnancies without preeclampsia            217                 1.0                  1.0
                                                  Two pregnancies, one episode of preeclampsia    38                  3.93 (2.79--5.55)    3.23 (2.25--4.63)
                                                  Two pregnancies, two episodes of preeclampsia   7                   6.70 (3.16--14.23)   5.30 (2.47--11.36)
  **4.**                                          **Diabetic CKD**                                                                         
                                                  Two pregnancies without preeclampsia            340                 1.0                  1.0
                                                  Two pregnancies, one episode of preeclampsia    73                  4.73 (3.67--6.10)    3.74 (2.88--4.86)
                                                  Two pregnancies, two episodes of preeclampsia   14                  8.44 (4.94--14.41)   6.80 (3.96--11.68)
  **5.**                                          **Other/unspecified CKD**                                                                
                                                  Two pregnancies without preeclampsia            2,651               1.0                  1.0
                                                  Two pregnancies, one of episode preeclampsia    179                 1.47 (1.26--1.71)    1.36 (1.16--1.58)
                                                  Two pregnancies, two episodes of preeclampsia   24                  1.77 (1.18--2.64)    1.64 (1.10--2.46)

\*All *p* \< 0.001

HRs represent separate Cox regression models for associations between preeclampsia and maternal CKD. Preeclampsia was a time-dependent variable. Fully adjusted models controlled for maternal age, country of origin, education level, parity, maternal BMI, smoking in pregnancy, exposure to gestational diabetes, and exposure to gestational hypertension. Models were stratified by year of delivery.

**Abbreviations:** CKD, chronic kidney disease; HR, hazard ratio

Sensitivity analysis {#sec017}
--------------------

When the dataset was restricted to first deliveries after 1987, some associations were strengthened. However, the overall results were not substantially different ([S4](#pmed.1003255.s006){ref-type="supplementary-material"}--[S6](#pmed.1003255.s008){ref-type="supplementary-material"} Tables). When births were stratified by maternal obesity at index pregnancy (from 1982), the association between preeclampsia and CKD was stronger in obese women (aHR 2.27, 95% CI 1.92--2.69) than it was for nonobese women (aHR 1.71, 95 CI 1.56--1.87, *p* for interaction \< 0.01) ([Table 5](#pmed.1003255.t005){ref-type="table"}). These differences persisted in analyses of preeclampsia ± SGA or preterm delivery, respectively, but not for recurrent preeclampsia. When women who developed postpartum hypertension were excluded from analyses, most associations between preeclampsia and CKD subtypes were attenuated, but not meaningfully different ([S7](#pmed.1003255.s009){ref-type="supplementary-material"}--[S9](#pmed.1003255.s011){ref-type="supplementary-material"} Tables).

10.1371/journal.pmed.1003255.t005

###### HRs for maternal CKD by history of preeclampsia, among women whose first live birth occurred between 1982 and 2012 in Sweden, stratified by maternal obesity (*n* = 1,011,939).

![](pmed.1003255.t005){#pmed.1003255.t005g}

                                                     All women           Women with normal BMI   Nonobese women      Obese women         *p*-Value for interaction
  -------------------------------------------------- ------------------- ----------------------- ------------------- ------------------- ---------------------------
  **Preeclampsia**                                                                                                                       
  No preeclampsia                                    1.0                 1.0                     1.0                 1.0                 *p* \< 0.01
  Preeclampsia (any)                                 1.83 (1.66--1.95)   1.62 (1.43--1.82)       1.71 (1.56--1.87)   2.27 (1.92--2.69)   
  **Preeclampsia and SGA**                                                                                                               
  No preeclampsia, no SGA                            1.0                 1.0                     1.0                 1.0                 *p* \< 0.01
  Preeclampsia only                                  1.85 (1.70--2.02)   1.63 (1.43--1.86)       1.75 (1.59--1.94)   2.35 (1.96--2.81)   
  SGA only                                           1.24 (1.13--2.04)   1.19 (1.05--1.35)       1.21 (1.09--1.34)   1.58 (1.15--2.17)   
  Preeclampsia and SGA                               1.66 (1.35--2.04)   1.61 (1.22--2.13)       1.58 (1.25--1.98)   2.20 (1.41--3.45)   
  **Preeclampsia and preterm delivery**                                                                                                  
  Term delivery, no preeclampsia                     1.0                 1.0                     1.0                 1.0                 *p* \< 0.01
  Moderate preterm delivery, no preeclampsia         1.38 (1.28--1.50)   1.38 (1.25--1.53)       1.35 (1.24--1.47)   1.65 (1.31--2.09)   
  Very/extremely preterm delivery, no preeclampsia   1.46 (1.18--1.79)   1.34 (1.01--1.77)       1.45 (1.16--1.81)   1.53 (0.86--2.72)   
  Term delivery + preeclampsia                       1.71 (1.55--1.88)   1.52 (1.32--1.75)       1.65 (1.49--1.84)   2.05 (1.68--2.51)   
  Moderate preterm delivery + preeclampsia           2.26 (1.89--2.70)   2.05 (1.58--2.66)       2.08 (1.68--2.56)   3.15 (2.22--4.46)   
  Very/extremely preterm delivery + preeclampsia     3.56 (2.67--4.74)   3.74 (2.48--5.63)       3.36 (2.40--4.71)   4.68 (2.70--8.12)   
  **Recurrent preeclampsia**                                                                                                             
  Two pregnancies without preeclampsia               1.0                 1.0                     1.0                 1.0                 *p* = 0.469
  Two pregnancies, one episode of preeclampsia       1.72 (1.52--1.96)   1.46 (1.20--1.77)       1.67 (1.44--1.93)   2.09 (1.58--2.77)   
  Two pregnancies, two episodes of preeclampsia      2.13 (1.55--2.94)   2.13 (1.30--3.49)       2.20 (1.52--3.20)   2.11 (1.12--3.98)   

Results were based on pregnancies for which data on BMI at first antenatal visit were available. BMI was only collected from 1982 onwards in the MBR. Analysis of recurrent preeclampsia was restricted to women who had two singleton live births from 1982 to 2012 inclusive, *n* = 482,845.

**Abbreviations:** aHR, adjusted hazard ratio; CKD, chronic kidney disease; SGA, small for gestational age

Gestational hypertension {#sec018}
------------------------

There were 43,964 women (2.3%) diagnosed with gestational hypertension at least once. Women who had ever experienced gestational hypertension were at increased risk of developing CKD (versus no gestational hypertension, aHR 1.49, 95% CI 1.38--1.61, *p* \< 0.001) ([S10 Table](#pmed.1003255.s012){ref-type="supplementary-material"}). The association was stronger for hypertensive CKD (aHR 3.13, 95% CI 2.47--3.97, *p* \< 0.001) and diabetic CKD (aHR 1.96, 95% CI 1.56--2.47, *p* \< 0.001), but did not persist for glomerular/proteinuric CKD.

When women who developed postpartum hypertension were excluded from analyses, the association with CKD was attenuated considerably (aHR 1.26, 95% CI 1.15--1.38, *p* = 0.006) ([S11 Table](#pmed.1003255.s013){ref-type="supplementary-material"}).

Discussion {#sec019}
==========

This study aimed to determine whether women who experience HDP are at risk of CKD and whether this risk differs by CKD aetiology. Overall, preeclampsia was associated with significantly increased risk of CKD, and the time to CKD diagnosis was 2.7 years shorter in women who previously had preeclampsia than in those who did not. Women diagnosed with gestational hypertension were also at increased risk of CKD, but the strength of this association was less marked.

Women exposed to HDP had strongly increased risk of hypertensive CKD and diabetic CKD. These associations are consistent with previous cohort studies, which reported that preeclampsia is associated with increased risk of postpartum hypertension and type 2 diabetes \[[@pmed.1003255.ref027]--[@pmed.1003255.ref030]\]. Although these CKD subtypes were less commonly diagnosed in our sample than other forms of renal disease, they are likely to become predominant causes of CKD in an older cohort with longer follow-up. By contrast, we observed less marked associations between preeclampsia and tubulointerstitial CKD or nonspecific CKD.

Glomerular/proteinuric CKD accounted for one-third of all CKD cases. Preeclampsia was associated with a doubling in risk of glomerular/proteinuric CKD, and the median time to diagnosis was 3.5 years shorter. Preeclampsia may lead to glomerular endotheliosis, which results in glomerular dysfunction, podocyte loss \[[@pmed.1003255.ref031], [@pmed.1003255.ref032]\] and subsequent microalbuminuria \[[@pmed.1003255.ref033], [@pmed.1003255.ref034]\]. Notably, no significant association was observed for gestational hypertension and glomerular/proteinuric CKD. This lends support to the hypothesis that the association between preeclampsia and CKD may be mediated through persistent glomerular damage, possibly related to down-regulation of NRF-2 \[[@pmed.1003255.ref012], [@pmed.1003255.ref035]\], and not entirely through the effects of hypertension or hyperglycaemia.

We examined whether concurrent SGA impacted on associations between preeclampsia and CKD. Previous longitudinal studies have reported an increased risk of CVD \[[@pmed.1003255.ref036]--[@pmed.1003255.ref038]\] and ESKD \[[@pmed.1003255.ref007]\] in women who had concurrent preeclampsia and SGA, but they used relatively broad composite outcomes. In our study, co-occurring SGA appeared to add to the risk of hypertensive CKD specifically, but it made little difference to the risk of other CKD aetiologies. Women who have both SGA and preeclampsia may experience more extreme placental dysfunction \[[@pmed.1003255.ref039]\], and it is plausible that this signals a higher risk of hypertensive disease in later life \[[@pmed.1003255.ref038]\]. Women who experienced SGA alone (without preeclampsia) were also at elevated risk of CKD, consistent with previous research \[[@pmed.1003255.ref007], [@pmed.1003255.ref040], [@pmed.1003255.ref041]\], but the modest increases observed in our study suggest that this may be of limited clinical importance.

Preeclampsia was associated with higher risk of CKD in obese women compared with women whose pre-pregnancy BMI was normal. Previous studies of preeclampsia and maternal renal disease have either adjusted for obesity without considering the possibility of effect modification \[[@pmed.1003255.ref015], [@pmed.1003255.ref042]\] or have lacked any information on maternal BMI \[[@pmed.1003255.ref007], [@pmed.1003255.ref016], [@pmed.1003255.ref041]\]. It is possible that women who develop preeclampsia have different cardio-renal risk profiles depending on their pre-pregnancy BMI. Pre-pregnancy obesity has been reported to be an independent risk factor for subsequent hypertension among women who ever experienced preeclampsia \[[@pmed.1003255.ref043]\]. Furthermore, women may have elevated markers of long-term endothelial dysfunction if they were overweight before developing preeclampsia \[[@pmed.1003255.ref044]\]. Although we restricted our analysis to women with complete information on antenatal BMI, we cannot rule out the possibility of unmeasured confounding from dyslipidaemia or recurrent preeclampsia, particularly if women with a first episode of preeclampsia received anti-hypertensive treatment or alternative cardio-protective intervention post partum.

Our findings support the need to optimise long-term follow-up of women exposed to HDP, and particularly high-risk women who experience preterm preeclampsia or recurrent preeclampsia. We did not have information on long-term blood pressure values for women in this study. It is uncertain whether screening for hypertension would suffice in preventing CKD or enabling earlier diagnosis of CKD in women with a history of preeclampsia. The additional value of screening for albuminuria is unknown and may depend on the underlying aetiology of CKD. However, it has been estimated that the number of patients with preeclampsia who need follow-up to detect one adverse event is about 4 for overt albuminuria and 157 for CKD, and the latter is likely to be a conservative overestimate \[[@pmed.1003255.ref045]\]. Early renal damage may be masked by compensatory glomerular hyperfiltration \[[@pmed.1003255.ref046]\], and this may also limit the ability to detect high-risk women until later in life. Thus, the optimal timing of engaging women in systematic renal and cardiovascular monitoring warrants further research. Nonetheless, 7% to 12% of all women will develop CKD in their lifetime \[[@pmed.1003255.ref047]--[@pmed.1003255.ref049]\], and the absolute risk of clinically significant disease is substantial.

Strengths and limitations {#sec020}
-------------------------

To our knowledge, this is the largest study to investigate associations between preeclampsia and CKD to date and the first to report associations between gestational hypertension and CKD subtypes. Its strengths include the use of national registry data with near-complete coverage and over 4 decades of follow-up \[[@pmed.1003255.ref020]\]; classification of CKD according to specific aetiologies; adjustment for a broader range of covariates than previous studies, including maternal smoking and BMI; exclusion of women with a large number of relevant pre-existing comorbidities, as well as congenital and genetic forms of CKD to reduce confounding; and the use of time-dependent covariates.

However, the study is not without limitations. Although the NPR achieved national coverage for inpatients in 1987, outpatient data were only available from 2001 onwards, and the overall incidence of CKD was lower than expected. The SRR collected data on CKD from 2007 and is unlikely to be complete \[[@pmed.1003255.ref050]\]. It is possible that cases of CKD were under-diagnosed or under-ascertained in the national registers; some women may have been too young to have developed symptomatic CKD despite their long follow-up time (median 21 years), and we cannot exclude the possibility of immortal time bias in our analysis. The NPR has high PPV for most diagnoses, but its sensitivity levels tend to be lower \[[@pmed.1003255.ref051]\], and to our knowledge these parameters have not been formally measured for CKD or its subtypes. Thus, while those who were diagnosed with CKD in our dataset are likely to have valid diagnoses, the number of undiagnosed cases is uncertain.

Hypertensive CKD and diabetic CKD were less commonly diagnosed than was anticipated, and this may have reflected lower sensitivity levels for these diagnoses or relatively short median follow-up times, or it may reflect relatively low levels of obesity and dysglycaemia among Swedish women \[[@pmed.1003255.ref052], [@pmed.1003255.ref053]\]. The respective PPVs for ICD-8 coded diagnoses of preeclampsia and gestational hypertension were lower than for ICD-9 diagnoses \[[@pmed.1003255.ref022]\], thus our overall results may be somewhat conservative. Our sensitivity analyses based on first deliveries after 1987 showed stronger associations between preeclampsia and CKD, but these were based on considerably fewer CKD cases, particularly when divided by CKD subtype.

Data on maternal BMI and smoking were incomplete and were only collected from 1982 onwards. We stratified by year of delivery in all our models and created a missing indicator variable to control for this. We cannot exclude the possibility of residual bias from using missing indicator variables. However, the results of our sensitivity analyses---when data on BMI were complete---were not substantially different.

Previous studies have controlled for postpartum hypertension when investigating associations between preeclampsia and cardiometabolic disease \[[@pmed.1003255.ref016], [@pmed.1003255.ref054]\], and despite an inherent risk of over-adjustment bias \[[@pmed.1003255.ref055]\], the associations appear to persist. In our sensitivity analyses, associations with CKD persisted after excluding women with postpartum hypertension. This suggests that other non-hypertensive factors also contribute to the development of maternal CKD. This analysis was limited to those diagnosed with hypertension in hospital settings during follow-up and may have missed a large number of women who were diagnosed with hypertension in community settings. Further research is required to delineate the role of mediating factors, such as postpartum hypertension, hyperglycaemia, hyperlipidaemia, and changes in maternal BMI, in the association between HDP and maternal CKD.

Conclusion {#sec021}
==========

Preeclampsia is associated with an increased risk of maternal CKD in the years following pregnancy. This risk is higher after preterm preeclampsia, recurrent preeclampsia, or in preeclampsia complicated by pre-pregnancy obesity. The risk differs by CKD aetiology and is most marked for hypertensive CKD, diabetic CKD, and glomerular/proteinuric CKD. Gestational hypertension is also associated with elevated risk of CKD, although associations are more modest than for preeclampsia. Women who experience HDP may benefit from systematic renal monitoring to prevent future CKD.
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We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Emma Veitch, PhD

PLOS Medicine

On behalf of Clare Stone, PhD, Acting Chief Editor,

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

\*The abstract should have a minor restructure, with the headings Background, Methods and Findings, Conclusions (Methods and Findings are a single combined section).

\*In the last sentence of the Abstract Methods and Findings section, would suggest including a brief description of the main limitation(s) of the study\'s methodology.

\*At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

\*Currently, the STROBE guideline is used to support study reporting (and provided as supporting information), this is good, but would also suggest including a mention of this somewhere in the Methods section (eg stating - \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (then call out the supporting information file)\".

\*Would also suggest clarifying in the Methods section of the paper whether the study had a prospective protocol or analysis plan. Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers:

Reviewer \#1: Review of PMED-D-20-00714-R1

This manuscript describes a study assess the effect of hypertensive disorders of pregnancy on incidence of chronic kidney disease. The long term effects of hypertensive disorders of pregnancy are important, and this manuscript offers a step forward in assessing these long term effects. However, I have several methodological concerns.

1\. The study was limited to women having live births. When estimating the effect of HDP on CKD, this offers 2 challenges: 1) there may be shared predictors of live birth (vs still birth or miscarriage) and CKD, which mean that the incidence of CKD is higher/lower among women who have at least one live birth than the total population of women who have ever been pregnancy (which may alter the estimated HR); and 2) if HPD affect the probability of having a live birth AND there is a common cause of live birth and CKD, restricting the study population to those with live births will cause a collider stratification bias (see Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C. Illustrating bias due to conditioning on a collider. International journal of epidemiology. 2010 Apr 1;39(2):417-20.). To avoid the first concern, the manuscript should clearly state that the relevant target population of interest is women who have had at least one live birth, rather than all women who have been pregnant. To avoid the second concern, I recommend against using causal language.

2\. The study excluded CKD diagnoses that occurred before a woman\'s last delivery. On page 7, line 178, the manuscript states that \"we only considered women who were diagnosed with CKD at least 3 months after the last pregnancy.\" This raises several questions and concerns. First, what happened to women who had a CKD diagnosis and then had another pregnancy/delivery? Moreover, excluding these diagnoses essentially makes the time between first and last delivery \"immortal\", which opens the door to a variety of immortal time biases. For example, this approach may omit women experiencing such a strong effect of HDP that they are diagnosed with CKD just 6 months after their first delivery (if they later go on to deliver 2 more children later in life). Typically, any outcome definition that requires looking into the future to classify patients as cases or not opens the door to bias. This is particularly true if there may be common causes of future pregnancies and CKD.

3\. Handling of competing events. Throughout, the analysis censored patients at death (I believe). If this is true, it should be stated explicitly. Moreover, a statement should be added to the definition of the parameter of interest and the interpretation of the results that the reported HRs are the HRs that would be seen could mortality be eliminated during the study period (see Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016 Feb 9;133(6):601-9). I also recommend presenting the results alongside results reporting overall mortality during the study period and, if overall mortality is not negligible, mortality by exposure group.

Specific points:

4\. Page 4, line 113: here, or in the statistical analysis section, please make it clear that deaths were censored (or clarify if this was not the case).

5\. Page 4, line 115: here, or in the results, please report how many were excluded based on each criterion.

6\. Page 6, line 160: minor point, but the parenthetical here I believe should read (32 weeks to 36 weeks + 6 days) to avoid confusion

7\. Page 6, line 165: please add a sentence of phrase here stating that this analysis was conducted only among women with exactly 2 deliveries. I was left wondering what the exposure definition was for women with \>2 deliveries and did not understand that this was conducted among a subset until the Results.

8\. Page 7, line 189: how were covariates selected?

9\. Page 7, line 195: the missing indicator method to account for missing data has been shown to produce biased results in many settings (see e.g., Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. American journal of epidemiology. 1995 Dec 15;142(12):1255-64.). Are there features of the current analysis that lead us to believe that it will work well here? If so, those should be stated.

10\. Page 8, line 200: from my understanding of the exposure definitions, women were considered to have gestational hypertension if they had a subset of the criteria for preeclampsia. If this is true, wouldn\'t these variables be perfectly collinear?

11\. Page 8, line 210: in models 2 through 4, the model form should be explained. Specifically, how was SGA modeled in model 2? Did the models include interaction terms between preeclampsia and SGA / preterm delivery?

12\. Page 9, line 239: how many CKDs were excluded because they occurred before woman\'s last delivery?

13\. Table 1: Is it correct to assume those in the \"Preeclampsia\" column were those who ever had a diagnosis of preeclampsia? If so, this should be noted (and if not, it should be clarified).

14\. Page 12, line 251: should the first sentence read \"Women who had ever experienced preeclampsia...\" (rather than \"ever experienced\") to make it clear that preeclampsia exposure was time varying?

15\. Page 21, line 357: should this be \"incidence\" rather than \"prevalence\"?

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#2: This is a well written paper in a Swedisch cohort where by this group the many other analysis have been done on ESRD, CKD in relation to prematurity. I do think that the paper is interesting but question whether is it novel enough in addition to the other papers.

1\. They do not have long-term blood pressure value of patients and therefor can not conclude that screening for renal function or albuminuria would have any additional value after preeclampsia. Screening for hypertension after preeclampsia and correcting for this while making statement on renal follow-up is essential

2\. Mechanisms of renal damage after preeclampsia can be multi-factorial. So far only marginal difference in sFlt1 are found as reviewed by Hypertension. 2016;68:00-00. DOI: 10.1161/HYPERTENSIONAHA.116.07907. NRF-2 is not a well know factor associated with glomerular damage in preeclampsia. Changes in the RAAS system, metabolic system and other factors causing endothelial dysfunction could be involved.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#3: This is an interesting and comprehensive analysis which has examined the long-term risk of CKD in women who developed hypertensive disorders in pregnancy. It represents a large and well curated dataset and provides important information which will inform the care and counselling of women who develop pregnancy complications. I have a number of questions listed below which I think could be clarified in the manuscript. Overall the data is well-described and clearly presented.

Why were still births excluded? I accept that sometimes difficult to know the cause but stillbirths in the context of preeclampsia/SGA (approx. 40% of stillbirths) should be included?

What was the comparator group(s) in the recurrent PE model? Are women with more than two pregnancies excluded from this analysis - needs clarification.

Definition (coding) of gestational hypertension? - women who only developed hypertension immediately after birth (ie within 6 weeks) or women who developed hypertension anytime after or between pregnancies? It would seem from the discussion that there is a distinct possibility that the diagnosis of post partum hypertension is under reported. This under reporting may significantly attenuate the association between pregnancy disease and CKD specifically - ie the association may be attributable to persistent hypertension (and/or diabetes) than pre-eclampsia per se? Should this perhaps be acknowledged in the abstract?

Whilst I understand the reason for excluding baseline hypertension diagnoses from the analysis - I wonder whether if this data is available whether it would be useful to compare the long term risk of CKD in this group of women which would provide a useful context comparison to the rates of CKD in women with de novo hypertension developing in pregnancy. I suspect this data is not available though?

Why do such a large number of CKD cases have non-specified CKD. Does the coding account for AKI related to another event which subsequently resolves?

Are the differences in time course significant? Should the different patterns of presentation of subsequent CKD be considered in follow up programmes?

Line 343 in discussion - what follow up would be required. Why do the authors consider this to be a conservative over estimate?

Line 344 - 7-12% in their lifetime population risk presumably includes a large amount of CKD in older age \>30years away from pregnancies and not covered by the time frame of the current analysis. The lifetime risk discussed here should be the population risk within the relevant time periods covered by the analysis presented which is not 7-12%?

Consider changing \"non-pre-eclamptic\" to women who had never had pre-eclampsia? Same for \"pre-eclamptic\" as a term in general.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003255.r003

Author response to Decision Letter 1

30 May 2020

###### 

Submitted filename: PLOS_Medicine Response Letter 300520.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003255.r004

Decision Letter 2

Stone

Clare

Senior Editor

© 2020 Clare Stone

2020

Clare Stone

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

26 Jun 2020

Dear Dr. Barrett,

Thank you very much for re-submitting your manuscript \"Hypertensive disorders of pregnancy and the risk of chronic kidney disease: a national registry-based cohort study\" (PMEDICINE-D-20-00714R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jul 03 2020 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Title -- please add the country setting

Abstract and throughout, please provide p values with quantifiable data and where 95% CIs are given

Please be more explicit in the abstract about the limitations of your study starting with 'Limitations of the study are....'

Please use square brackets for refs in the main text.

Please break the supp files into separate ones and the STROBE needs to be provided with sections and paragraphs instead of page numbers

At line 74, \"In this study, we found that \... were associated \...\" or similar.

At line 102, \"Our findings suggest that \...\" or similar.

Methods, was there a protocol or prespecified analysis plan?

Comments from Reviewers:

Reviewer \#1: Overall, this revision is very responsive to my previous comments. A few minor points are added below:

1\. Page 11, line 286: Presumably this is time to CKD diagnosis \*after first live birth\*?

2\. Page 6, line 174: I found this sentence confusing. I thought the current study included all women who had live singleton births during/after 1973, not limited to those with preeclampsia after 1973. I recommend rewording this sentence to clarify that analyses were repeated after restricting the entire study population to those with a first live birth from 1987 onwards.

3\. Page 9, line 234: I recommend clarifying that \"missing indicators were used to account for missing data on smoking and BMI\" (as opposed to ending the sentence with \"this\"). As a side note, I accept the authors\' logic that, because results were similar after sensitivity analysis that limited the study population to 1987 and after, when there was less missing data, the missing indicator method was unlikely to have induced substantial bias. However, I still have concerns about use of the missing indicator method in this setting and recommend adding language to the discussion acknowledging the potential for (or at least possibility of) residual bias when using this approach.

Reviewer \#3: Comments considered and addressed.

The manuscript has been significantly improved, I have no further suggestions/comments.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003255.r005

Author response to Decision Letter 2

13 Jul 2020

###### 

Submitted filename: Responses to Reviewer Comments 260620.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003255.r006

Decision Letter 3

Stone

Clare

Senior Editor

© 2020 Clare Stone

2020

Clare Stone

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

15 Jul 2020

Dear Dr Barrett,

On behalf of my colleagues and the academic editor, Dr. Jenny Myers, I am delighted to inform you that your manuscript entitled \"Hypertensive disorders of pregnancy and the risk of chronic kidney disease: a Swedish registry-based cohort study\" (PMEDICINE-D-20-00714R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal's policy and the authors of this manuscript have the following competing interests: ME has participated in advisory board meetings (Astellas, Astra Zeneca, Vifor Pharma) and has received payment for lectures (Astellas, Vifor Pharma).

[^2]: ‡ These authors are joint senior authors on this work and contributed equally.
